GRIN Europe is very excited to share with you this press release in which Neurvati Neurosciences/GRIN Therapeutics, Inc. announces the initiation of its pivotal Phase 3 Beeline study in Europe, further advancing its global clinical program evaluating investigational radiprodil for GRIN-related neurodevelopmental disorder (GRIN-NDD).
Building on the very encouraging clinical results of the Honeycomb Trial, for the Beeline Trial, trial sites will be initiated in Belgium, France, Germany, Italy, Poland, the Netherlands, Slovenia and Spain.
You can find the press release here: